Last reviewed · How we verify
MCT-SR
MCT-SR is a sustained-release formulation of medium-chain triglycerides designed to improve lipid absorption and nutritional support.
MCT-SR is a sustained-release formulation of medium-chain triglycerides designed to improve lipid absorption and nutritional support. Used for Nutritional support in malabsorption disorders, Lipid supplementation in patients with impaired fat digestion.
At a glance
| Generic name | MCT-SR |
|---|---|
| Sponsor | Korea Otsuka Pharmaceutical Co., Ltd. |
| Drug class | Nutritional supplement / Lipid formulation |
| Modality | Small molecule |
| Therapeutic area | Nutrition / Metabolic support |
| Phase | Phase 3 |
Mechanism of action
Medium-chain triglycerides (MCTs) are fatty acids with 6-12 carbon chains that are more readily absorbed in the gastrointestinal tract compared to long-chain triglycerides. The sustained-release formulation extends the duration of MCT availability in the body, potentially improving bioavailability and reducing gastrointestinal side effects associated with standard MCT formulations.
Approved indications
- Nutritional support in malabsorption disorders
- Lipid supplementation in patients with impaired fat digestion
Common side effects
- Gastrointestinal distress
- Diarrhea
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MCT-SR CI brief — competitive landscape report
- MCT-SR updates RSS · CI watch RSS
- Korea Otsuka Pharmaceutical Co., Ltd. portfolio CI